medigraphic.com

2010, Number 2

<< Back Next >>

Rev Med Hosp Gen Mex 2010; 73 (2)

Prevalence of hepatitis C antibodies in blood donors of the Hospital General de México

Gómez-Hernández G, Reyes-Islas E, Abdo-Francis JM, Chávez-Mayol JM

Language: Spanish
References: 32
Page: 88-93
PDF size: 133.93 Kb.


ABSTRACT

Introduction: Is estimated that around 170 million individuals are infected with hepatitis C virus (HCV) in the world, representing a main cause of morbidity and mortality. In the United States, before 1990 transmission was mainly associated with blood transfusion and drug injections, while in Mexico the main mode of transmission was the former. After 1990, several publications report a prevalence of antibodies against hepatitis C virus in blood donors ranging from 0.195% to 6%. Objective: To determine the prevalence of antibodies against hepatitis C virus in blood donors at the General Hospital of Mexico. Material and methods: The study included blood donors who met the requirements of NOM-003-SSA-2-1993 «Official Mexican Regulations …for the disposal of human blood and blood components for therapeutic purposes», in the period from 2007 to 2009. Inclusion criteria: accepted donors who had positive anti-HCV ELISA and RIBA positive confirmatory test. Statistical analysis used average, percentage, range and 95% confidence intervals. Results: 60.423 donors were accepted, 473 (0.78%) had anti-HCV, of whom 96 (20.3%) (CI95% 17 to 24), had a positive confirmatory test. The prevalence of confirmed by RIBA HCV was 0.16 (CI95% 0.13 to 0.19). Conclusions: The prevalence of HCV in blood donors of the Hospital General of Mexico in the period 2007-2009 is lower than the reported in other national and international publications.


REFERENCES

  1. Simmonds P. Genetic diversity and evolution of hepatitis C virus 15 years on. J Gen Virol 2004; 85: 3173-3188.

  2. Alter MJ, Kruszon-Moran D, Nainan O et al. The prevalence of hepatitis C virus in the United States. N Engl J Med 1999; 341: 556-562.

  3. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327: 1899-1905.

  4. Ohto H, Terazawa S, Sasaki N et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330: 744-750.

  5. Wyld R, Robertson JR, Brettle RP, Mellor J, Prescott L, Simmonds P. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals. J Infect 1997; 35: 163-166.

  6. Sánchez A, Robles Díaz G. Hepatitis post-transfusión: Comienzo y desaparición. Rev Gastroenterol Mex 1994; 59: 324-330.

  7. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepúlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿Un problema de salud pública emergente? Sal Pub Mex 2007; 49 (supl 3): S395-S403.

  8. Buseri FI, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, South-West Nigeria. Blood Transfus 2009; 7 (4): 293-299.

  9. Williams A, Dodd R. The serology of hepatitis C virus in relation to post-transfusion hepatitis. Ann Clin Lab Sci 1990; 20: 192-199.

  10. Muller Z, Deak J et al. The detection of Hepatitis C virus in South Hungary. J Clin Virol 2001; 20: 81-83.

  11. Williams A, Dodd R. The serology of hepatitis C virus in relation to post-transfusion hepatitis. Ann Clin Lab Sci 1990; 20: 192-199.

  12. Rosini N, Mousse D, Spada C, Treitinger A. Seroprevalence of HBsAg, antiHBc and antiVHC in Southern Brazil, 1999-2001. Vraz J Infect Dis 2003; 7: 262-267.

  13. Vázquez-Flores J, Valiente-Banuet L, Marín L, Sánchez-Guerrero A. La seguridad de las reservas sanguíneas en la República Mexicana durante los años 1999 a 2003. Rev Invest Clin 2006; 58 (2): 101-108.

  14. Guerrero-Romero JF, Castañeda A, Rodríguez-Morán M. Prevalence and risk factors associated to hepatitis «C» in blood donors in Durango, Mexico. Sal Pub Mex 1996; 38: 94-100.

  15. Ayala JJ, Guerra FJ, Mora P, Casillas A. Prevalencia de marcadores virales para hepatitis B, C y virus de inmunodeficiencia humana en donadores de sangre voluntarios en el Noroeste de México. Rev Gastroenterol Mex 1997; 62: 250-253.

  16. Hernández-Pérez RE, Frías-Salcedo JA, Del Ángel-Guevara O. Seroprevalencia de anticuerpos contra el virus de la hepatitis C en donadores de sangre del Hospital Central Militar. Sal Pub Mex 1994; 36: 538-540.

  17. Valerio-Ureña J, Vásquez-Fernández F et al. Prevalencia de marcadores serológicos de VHB y VHC en donadores de sangre de la ciudad de Veracruz. Gac Med Mex 2009; 3: 183-187.

  18. García-Montalvo Beatriz M. Seropositividad de VIH, VHB, VHC y Treponema pallidum en el Sureste de México. Rev Inv Clin Mex 2006; 6: 567-572.

  19. Rivera-López MR, Zavala-Méndez C, Arenas-Esqueda A. Prevalencia de seropositividad para VIH, hepatitis B y C en donadores de sangre. Gac Med Mex 2004; 6: 660-667.

  20. Suoto-Meriño CA, Simón-Domínguez J, Pulido-Priego MA, Hernández-Pérez A, García-Hernández IC, Del Río-Chiriboga CA. Prevalencia de marcadores para hepatitis A, B y C en un hospital de México. Sal Pub Mex 1994; 36: 257-262.

  21. Merino-Conde E, Orozco JA, Rojo-Medina J, Tovar A. Prevalence of hepatitis C virus among candidates for blood donation at the Hospital General de México. In Vivo 1994; 8 (4): 621-623.

  22. Méndez-Sánchez N, Baptista-González H, Sánchez-Gómez RH, Bordes-Aznar J, Uribe-Esquivel M. Prevalencia de hepatitis B y C en donadores de sangre en un hospital de tercer nivel de la Ciudad de México. Sal Pub Mex 1999; 41: 475-478.

  23. Lauer GM, Walker BD. Hepatitis C Virus Infection. N Engl J Med 2001; 345 (1): 41-52.

  24. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A et al. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003; 43: 696-704.

  25. Dreier J, Kröger M, Diekmann J, Götting C, Kleesiek K. Lowlevel viraemia of hepatitis B virus in an anti-HBc- and anti-HBs positive blood donor. Transfusion Med 2004; 14: 97-103.

  26. Baptista-González Héctor. Lo que no sabemos y lo que debemos saber acerca de las pruebas moleculares en el tamiz de infecciones transmitidas por infección en donadores de sangre en México. Rev Mex Med Tran 2009: 1: 30-40.

  27. Villanueva-Méndez M, Experiencia de la prueba de NAT en el banco de sangre del Instituto Nacional de Cancerología, México, D.F. Rev Mex Med Tran 2009; 1 (supl 1): 569-571.

  28. Benítez-Arvizu G, Cortez-Gómez R, Novelo-Garza BA, Malagón-Martínez A, Guerra-Márquez A et al. Prevalencia del virus de hepatitis C en el Banco de Sangre del Centro Médico Nacional La Raza. Rev Med Inst Mex Seguro Soc 2006; 44 (3): 227-233.

  29. Sosa-Jurado F, Santos-López G, Guzmán-Flores B, Ruiz-Conde JI, Meléndez-Mena D et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 2010; 7: 18.

  30. Carreto-Vélez MA, Carrada-Bravo T, Martínez-Magdaleno A. Seroprevalencia de VHB, VHC y VIH en Donadores de Sangre en Irapuato, México. Sal Pub Mex 2002; 45 (supl 5): S690-S693.

  31. Lai PP, Hwang SH, Lee SY, Co RL, Chien D, Kuo G. Evaluation of sexual transmission in patients with chronic hepatitis C infection. Clin Diag Virol 1995; 3 (1): 39-47.

  32. Norma Oficial Mexicana NOM-003-SSA2-1993, Para la disposición de sangre humana y sus componentes con fines terapéuticos. Publicada en el Diario Oficial de la Federación el 8 de diciembre de 1993.




2020     |     www.medigraphic.com